John F. Sheridan - May 17, 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
PRESIDENT & CEO, Director
Signature
s/ David B. Berger , Attorney-in-Fact for John F. Sheridan
Stock symbol
TNDM
Transactions as of
May 17, 2021
Transactions value $
$19,761
Form type
4
Date filed
5/20/2021, 09:38 PM
Next filing
Jun 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Award $19.8K +296 +7.88% $66.76 4.05K May 17, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Restricted Stock Unit Award $0 +12.7K $0.00 12.7K May 18, 2021 Common Stock 12.7K Direct F2, F3, F4
transaction TNDM Performance Stock Unit Award $0 +12.7K $0.00 12.7K May 18, 2021 Common Stock 12.7K Direct F2, F5
transaction TNDM Stock Option Award $0 +38.7K $0.00 38.7K May 18, 2021 Common Stock 38.7K $81.63 Direct F2, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 17, 2020 through May 17, 2021. This transaction is also exempt under Rule 16b-3(c).
F2 Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F3 Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
F4 RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one-year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.
F5 Each performance stock unit ("PSU") represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the "Company") common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the "Measurement Date"). The number of shares issued may range from 0% to 200 % of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSU's will vest.
F6 The option shall vest as to twenty-five percent (25%) of the underlying shares on the one-year anniversary of the grant date, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of the 2013 Plan.
F7 The expiration date for these options is 10 years from the date of grant.